Patents by Inventor Mutsumi SEKI

Mutsumi SEKI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-human Ig? antibody
    Patent number: 11059889
    Abstract: Described herein are novel anti-human Ig? antibodies, as well as methods for making the antibodies and using the antibodies to treat or prevent autoimmune disease.
    Type: Grant
    Filed: April 23, 2019
    Date of Patent: July 13, 2021
    Assignee: Astellas Pharma Inc.
    Inventors: Daisuke Yamajuku, Mutsumi Seki, Takashi Honda, Satoshi Kubo, Shinji Soga, Akifumi Morinaka
  • NOVEL ANTI-HUMAN Igß ANTIBODY
    Publication number: 20190309063
    Abstract: Described herein are novel anti-human Ig? antibodies, as well as methods for making the antibodies and using the antibodies to treat or prevent autoimmune disease.
    Type: Application
    Filed: April 23, 2019
    Publication date: October 10, 2019
    Applicant: Astellas Pharma Inc.
    Inventors: Daisuke YAMAJUKU, Mutsumi SEKI, Takashi HONDA, Satoshi KUBO, Shinji SOGA, Akifumi MORINAKA
  • Anti-human Ig? antibody
    Patent number: 10316086
    Abstract: [Problem] Provided is an anti-human Ig? antibody which crosslinks BCR and Fc?RIIb and has an immunosuppressive function more enhanced than that of an antibody in the prior art. [Means for Solution] An anti-human Ig? antibody comprising a heavy chain variable region comprising CDR1 consisting of the amino acid sequence of amino acid numbers 31 to 35 of SEQ ID NO: 2, CDR2 consisting of the amino acid sequence of amino acid numbers 50 to 65 of SEQ ID NO: 2, and CDR3 consisting of the amino acid sequence of amino acid numbers 98 to 108 of SEQ ID NO: 2, a light chain variable region comprising CDR1 consisting of the amino acid sequence of amino acid numbers 24 to 38 of SEQ ID NO: 4, CDR2 consisting of the amino acid sequence of amino acid numbers 54 to 60 of SEQ ID NO: 4, and CDR3 consisting of the amino acid sequence of amino acid numbers 93 to 101 of SEQ ID NO: 4, and a heavy chain constant region which is a human Ig?1 constant region having amino acid mutations of S239D, H268D, and L328W.
    Type: Grant
    Filed: August 5, 2015
    Date of Patent: June 11, 2019
    Assignee: ASTELLAS PHARMA INC.
    Inventors: Daisuke Yamajuku, Mutsumi Seki, Takashi Honda, Satoshi Kubo, Shinji Soga, Akifumi Morinaka
  • NOVEL ANTI-HUMAN IgB ANTIBODY
    Publication number: 20170226207
    Abstract: [Problem] Provided is an anti-human Ig? antibody which crosslinks BCR and Fc?RIIb and has an immunosuppressive function more enhanced than that of an antibody in the prior art. [Means for Solution] An anti-human Ig? antibody comprising a heavy chain variable region comprising CDR1 consisting of the amino acid sequence of amino acid numbers 31 to 35 of SEQ ID NO: 2, CDR2 consisting of the amino acid sequence of amino acid numbers 50 to 65 of SEQ ID NO: 2, and CDR3 consisting of the amino acid sequence of amino acid numbers 98 to 108 of SEQ ID NO: 2, a light chain variable region comprising CDR1 consisting of the amino acid sequence of amino acid numbers 24 to 38 of SEQ ID NO: 4, CDR2 consisting of the amino acid sequence of amino acid numbers 54 to 60 of SEQ ID NO: 4, and CDR3 consisting of the amino acid sequence of amino acid numbers 93 to 101 of SEQ ID NO: 4, and a heavy chain constant region which is a human Ig?1 constant region having amino acid mutations of S239D, H268D, and L328W.
    Type: Application
    Filed: August 5, 2015
    Publication date: August 10, 2017
    Applicant: Astellas Pharma Inc.
    Inventors: Daisuke YAMAJUKU, Mutsumi SEKI, Takashi HONDA, Satoshi KUBO, Shinji SOGA, Akifumi MORINAKA